Jana Jiráčková1,2,3, Radomir Hyšpler4,5, Sumaya Alkanderi6, Ladislava Pavlíková4,5, Vladimir Palicka4,5, John A Sayer6,7,8. 1. Institute for Clinical Biochemistry and Diagnostics, Department of Clinical Osteology, University Hospital Hradec Králové, Hradec Králové, Czechia, jana.jirackova@fnhk.cz. 2. Department of Gerontology and Metabolism, University Hospital Hradec Králové, Hradec Králové, Czechia, jana.jirackova@fnhk.cz. 3. Faculty of Medicine, Charles University, Hradec Králové, Czechia, jana.jirackova@fnhk.cz. 4. Institute for Clinical Biochemistry and Diagnostics, Department of Clinical Osteology, University Hospital Hradec Králové, Hradec Králové, Czechia. 5. Faculty of Medicine, Charles University, Hradec Králové, Czechia. 6. Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom. 7. Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle, United Kingdom. 8. NIHR Newcastle Biomedical Research Centre, Newcastle, United Kingdom.
Abstract
BACKGROUND/AIMS: The CYP24A1 gene encodes the vitamin D 24-hydroxylase enzyme, which hydroxylates active forms of vitamin D into inactive forms. Biallelic mutations in the CYP24A1 gene can lead to elevated levels of active vitamin D metabolites and, consequently, to hypercalcemia, hypercalciuria, nephrocalcinosis, and nephrolithiasis; however, monoallelic mutations have been associated only with milder phenotypes. In the present manuscript, we report the case of a young male patient who presented hypercalcemia and nephrolithiasis, suppressed parathormone, and elevated 1,25 dihydroxy vitamin D levels. METHODS: Biochemical analyses were performed on Cobas 8000, F. Hoffmann-La Roche AG, Basel, Switzerland. The proband was initially evaluated for occult malignancies by body imaging, serum electrophoresis, and tumor markers, which did not reveal any pathology. DNA samples of the proband and his sibling were then examined using Sanger sequencing. RESULTS: Genetic analysis revealed 2 compound heterozygous CYP24A1 mutations (p.L148P and p.R223*). The novel nonsense CYP24A1 mutation, p.R223*, was also found heterozygously in other family members with a medical history of nephrolithiasis. CONCLUSIONS: The identification of this gene mutation causing hypercalcemia, hypercalciuria, and renal stones allows the specific management of endogenous vitamin D production.
BACKGROUND/AIMS: The CYP24A1 gene encodes the vitamin D 24-hydroxylase enzyme, which hydroxylates active forms of vitamin D into inactive forms. Biallelic mutations in the CYP24A1 gene can lead to elevated levels of active vitamin D metabolites and, consequently, to hypercalcemia, hypercalciuria, nephrocalcinosis, and nephrolithiasis; however, monoallelic mutations have been associated only with milder phenotypes. In the present manuscript, we report the case of a young male patient who presented hypercalcemia and nephrolithiasis, suppressed parathormone, and elevated 1,25 dihydroxy vitamin D levels. METHODS: Biochemical analyses were performed on Cobas 8000, F. Hoffmann-La Roche AG, Basel, Switzerland. The proband was initially evaluated for occult malignancies by body imaging, serum electrophoresis, and tumor markers, which did not reveal any pathology. DNA samples of the proband and his sibling were then examined using Sanger sequencing. RESULTS: Genetic analysis revealed 2 compound heterozygous CYP24A1 mutations (p.L148P and p.R223*). The novel nonsense CYP24A1 mutation, p.R223*, was also found heterozygously in other family members with a medical history of nephrolithiasis. CONCLUSIONS: The identification of this gene mutation causing hypercalcemia, hypercalciuria, and renal stones allows the specific management of endogenous vitamin D production.
Authors: Chenyu Wang; Ran Du; Jieyuan Jin; Yi Dong; Jishi Liu; Liangling Fan; Rong Xiang Journal: Am J Transl Res Date: 2020-08-15 Impact factor: 4.060
Authors: Maria De Bonis; Elisa De Paolis; Maria Elisabetta Onori; Giorgia Mazzuccato; Antonio Gatto; Pietro Ferrara; Pietro Manuel Ferraro; Andrea Urbani; Angelo Minucci Journal: Mol Biol Rep Date: 2021-04-17 Impact factor: 2.316
Authors: Agnieszka Janiec; Paulina Halat-Wolska; Łukasz Obrycki; Elżbieta Ciara; Marek Wójcik; Paweł Płudowski; Aldona Wierzbicka; Ewa Kowalska; Janusz B Książyk; Zbigniew Kułaga; Ewa Pronicka; Mieczysław Litwin Journal: Nephrol Dial Transplant Date: 2021-07-23 Impact factor: 5.992